Agonistic CD40 antibody therapy induces tertiary lymphoid structures but impairs the response to immune checkpoint blockade in glioma
L. van Hooren, A. Vaccaro, M. Ramachandran, K. Vazaios, S. Libard, T. van de Walle, M. Georganaki, H. Huang, I. Pietilä, J. Lau, M. H. Ulvmar, M. C. Karlsson, M. Zetterling, S. M. Mangsbo, A. S. Jakola, , A. Dimberg
This study shows that agonistic CD40 antibody therapy in glioma models causes T cell dysfunction and reduces response to checkpoint inhibitors, but also promotes tertiary lymphoid structures associated with improved T cell infiltration.
bioRxiv · Jan 5, 2021Cancer Biology